• Immunofluorescence analysis of HepG2 cells, Antibody diluted at 1:50. The picture on the right is blocked with the synthesized peptide.
  • Western blot analysis of MOUSE-LIVER cells using Phospho-TGF Beta RI (S165) Polyclonal Antibody diluted at 1:1000
  • Immunohistochemical analysis of paraffin-embedded Rat-kidney tissue. 1, TGF Beta RI (phospho Ser165) Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunohistochemical analysis of paraffin-embedded Rat-spleen tissue. 1, TGF Beta RI (phospho Ser165) Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunohistochemical analysis of paraffin-embedded Human-liver tissue. 1, TGF Beta RI (phospho Ser165) Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.

Anti-Phospho-TGFBR1-Ser165 antibody (131-180 aa) (STJ91351)

SKU:
STJ91351

Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Phospho-TGF-beta receptor type-1-Ser165 (131-180 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-2000
IF 1:50-300
IHC 1:50-300
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: TGFBR1
Gene ID: 7046
Uniprot ID: TGFR1_HUMAN
Immunogen Region: 131-180 aa
Specificity: Phospho-TGF Beta RI (S165) Polyclonal Antibody detects endogenous levels of TGF Beta RI protein only when phosphorylated at S165.
Immunogen: The antiserum was produced against synthesized peptide derived from the human TGF beta Receptor I around the phosphorylation site of Ser165 at the amino acid range 131-180
Post Translational Modifications Phosphorylated at basal levels in the absence of ligand. Activated upon phosphorylation by TGFBR2, mainly in the GS domain. Phosphorylation in the GS domain abrogates FKBP1A-binding. N-Glycosylated. Ubiquitinated.undergoes ubiquitination catalyzed by several E3 ubiquitin ligases including SMURF1, SMURF2 and NEDD4L2. Results in the proteasomal and/or lysosomal degradation of the receptor thereby negatively regulating its activity. Deubiquitinated by USP15, leading to stabilization of the protein and enhanced TGF-beta signal. Its ubiquitination and proteasome-mediated degradation is negatively regulated by SDCBP.
Function Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.
Protein Name Tgf-Beta Receptor Type-1
Tgfr-1
Activin A Receptor Type Ii-Like Protein Kinase Of 53kd
Activin Receptor-Like Kinase 5
Alk-5
Alk5
Serine/Threonine-Protein Kinase Receptor R4
Skr4
Tgf-Beta Type I Receptor
Transforming Growth Factor-Beta Receptor Type I
Tgf-Beta Receptor Type I
Tbetar-I
Database Links Reactome: R-HSA-2173788
Reactome: R-HSA-2173789
Reactome: R-HSA-2173791
Reactome: R-HSA-3304356
Reactome: R-HSA-3645790
Reactome: R-HSA-3656532
Reactome: R-HSA-3656535
Reactome: R-HSA-5689603
Reactome: R-HSA-5689880
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Cell Junction
Tight Junction
Cell Surface
Membrane Raft
Alternative Antibody Names Anti-Tgf-Beta Receptor Type-1 antibody
Anti-Tgfr-1 antibody
Anti-Activin A Receptor Type Ii-Like Protein Kinase Of 53kd antibody
Anti-Activin Receptor-Like Kinase 5 antibody
Anti-Alk-5 antibody
Anti-Alk5 antibody
Anti-Serine/Threonine-Protein Kinase Receptor R4 antibody
Anti-Skr4 antibody
Anti-Tgf-Beta Type I Receptor antibody
Anti-Transforming Growth Factor-Beta Receptor Type I antibody
Anti-Tgf-Beta Receptor Type I antibody
Anti-Tbetar-I antibody
Anti-TGFBR1 antibody
Anti-ALK5 antibody
Anti-SKR4 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance